Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2 CAR-T for GD2+ Glioma
NCT03252171Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Oct 2015
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial in glioma, sponsored by Fuda Cancer Hospital. Primary endpoint: Effectiveness of CAR-T cell immunotherapy at 3 months. Planned start Oct 2015; status: withdrawn.
02
Conditions
glioma
Beyond the preview
Go deeper on NCT03252171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252171.